Log in
Enquire now
‌

US Patent 10953000 Combination of pimavanserin and cytochrome P450 modulators

Patent 10953000 was granted and assigned to Acadia Pharmaceuticals on March, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Acadia Pharmaceuticals
Acadia Pharmaceuticals
0
Date Filed
March 23, 2017
0
Date of Patent
March 23, 2021
0
Patent Application Number
16087604
0
Patent Citations
‌
US Patent 10449185 Formulations of pimavanserin
‌
US Patent 10646480 Formulations of pimavanserin
‌
US Patent 10525046 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
‌
US Patent 10028944 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
‌
US Patent 10517860 Combination of pimavanserin and cytochrome P450 modulators
Patent Citations Received
‌
US Patent 11840515 Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
0
‌
US Patent 11648242 Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof
0
‌
US Patent 11464768 Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
Patent Inventor Names
Andrew Parkinson
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
10953000
0
Patent Primary Examiner
‌
Sarah Pihonak
0

Find more entities like US Patent 10953000 Combination of pimavanserin and cytochrome P450 modulators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.